Looks like the seller for this block trade was found on the board. I wonder if there will be a notification for the other side as well?
edit.
This is what I was speculating and also slightly implying 
5 Likes
It will only happen if the buyer is an insider or if the buyerâs position exceeds the flagging threshold due to the trade. Otherwise, the information will be found on the shareholder list at the end of the month, or it could probably be found even now at Euroclearâs office in Kamppi if you can be bothered to go there in person 
6 Likes
âWhen an investor learns that the companyâs chairman of the board, CEO, or another person in a key position has sold a significant amount of the companyâs shares, it is best for them to do exactly the same, regardless of the stated reason for the trade. The reasons given to the public are often excuses. Who would have better information or an inkling of the development of the company and its share value than the companyâs management?â - Seppo Saario
11 Likes
Apparently, Johan Lundin had 1.25 million shares at the turn of the month.
If he wasnât particularly wealthy before taking Aiforia public, then a reduction of just over 20% and a million-euro sell-off falls, in my opinion, under sensible risk management, or maybe thereâs a pipe renovation coming up, and to avoid it, heâs swapping one pad for anotherâŠ
Although management selling isnât exactly a positive signal, especially with the near future in mind. Otherwise, it would have been worth waiting for a while instead of selling near the yearâs lows.
5 Likes
Of course, a larger expense can surprise you at any time, such as an acute need for a yacht or a summer cottage, so the excuses can be real as well.
And then in reality, many people in these high-risk growth companies are just regular folks and suddenly all their eggs are in one basket, or actually, one egg in one basket. I do allow for sensible portfolio balancing, as long as a good amount of firepower is left in that egg. Only if an omelet is made out of all the eggs is there a reason to follow suit.
6 Likes
at first glance, one might think that the buyer is some institution or fund management company⊠a new anchor investor, and thatâs good. The market is waiting for good deals and AI is the future. Microsoft is investing in AI healthcare solutions, and what are the potential companies that the investments will be directed towards. Cancer research is gaining significant momentum, and a link to the pharmaceutical industry would be desirable
5 Likes
As a reminder, Aiforia will be at the company evening today starting around 4:15 PM. Questions can be sent to the event chat or directly to me.
15 Likes
New partner:
32 Likes
You could ask what kind of cash flow comes from the Turkish agreement? How have sales and invoicing developed in other partnerships? Could we get some kind of summary and analysis of the CEOâs presentation from this presentation?
4 Likes
Analystâs comments on Turkeyâs trade news.
We have included new deals in our forecasts and have been awaiting related announcements from the company, so the announcement is not a surprise or cause for immediate pressure to change forecasts. Naturally, however, the announcement supports our forecasts and is another sign that Aiforiaâs solution is competitive in the market and that market formation in Europe continues.
14 Likes
Here is a direct link to CEO Jukka Tapaninenâs yesterdayâs presentation on Aiforia as an investment. 
12 Likes
At least the CEO believes in the company and bought shares.
26 Likes
The article discusses the adoption of digital pathology in Britain and highlights several challenges encountered in this type of project. However, the project is progressing and expanding rapidly.
âIn the new year we plan to start the two remaining projects with Bolton NHS Foundation Trust and The Christie NHS Foundation Trust, with the aim of concluding the roll-out at all seven labs in early 2026.â
Itâs interesting that Aiforia is not mentioned in the articleâs text, but the illustrations feature Aiforiaâs material.
https://thebiomedicalscientist.net/2024/12/02/future-digital-greater-manchester-diagnostics-network
23 Likes
An interesting observation indeed, could there be an explanation that the said magazine is British and the article in question dealt with Britainâs own digital project. So, would it be a classic case of favoring oneâs own? Perhaps Aiforia should complain about the use of its materials?
4 Likes
CEO Jukka Tapaninen and board member Tuomas Tenkanen are also heading to the JP Morgan Healthcare Conference on Jan 13-15.
Tuomas is known for his golden touch in biotech, first with Finnzymes and then the Mobidiag exit. https://keskustelut.inderes.fi/t/aiforia-laaketieteen-kuva-analyysiohjelmistoja/25362/306?u=vino_pino
He now owns at least one percent of Aiforia through TJT Technologies. Jukka has a bit more, just over two percent of the company. They canât sell the company at JPM and itâs probably not even timely yet. Deals are sometimes announced at JP Morgan, but networking is also important for the future. If Aiforia still needed money, I suggest a direct offering to Tuomas, as money seems to grow there 
@Antti_Luiro, Iâve been meaning to ask, what is your analysis of the phenomenon where competing digital pathology players form cross-collaboration agreements? Like Paige and Aiforia in November. This, of course, ensures that each retains some market share, but this âeveryone plays with everyoneâ approach probably leads to reduced competition and ultimately no winners. Or perhaps everyone, but less? Risk decreases, but so does reward? It would be understandable if two or three alliances were seen to be forming to compete for the market. That would probably be the so-called normal situation after consolidation? Forecast? Is there a comparable situation somewhere for the formation of such a new market?
28 Likes
Letâs shift into vision mode but yep, I see a certain platform game underway here, where roughly 80% of the market will concentrate on about 2-5 players as a constant.
Pathology labs process large volumes, and the process needs to be very smooth. A lab doesnât want to adopt and pay for many separate image analysis software programs, each of which would need to be integrated into multiple systems separately, learned to use separately, and pathologists would have to switch between systems. Fundamentally, only one platform will be adopted.
However, itâs very possible that this one platform doesnât offer a good enough image recognition model for every application â Itâs important for the customer not to be completely locked out of other ecosystem players (and their models) when choosing a solution. Fundamentally, the best general platform that brings the greatest automation benefits (of course, at the required quality level) is chosen for image analysis. Aiforia is currently strong in this, because the clinical side is advanced compared to its peers (models are available sufficiently for the initial phase, and sample analysis automation goes further than many competitors) and the same platform can be used on the labâs research side.
Platforms/model providers with weaker competitiveness are forced to form partnerships with other players because they havenât managed to get their own platform (and image recognition models) to gain traction in the clinical market, and otherwise, they have no way to access clinical volumes. Of course, this doesnât fix the competitiveness of their models (e.g., âCancer/no cancer â pathologist starts manually counting if they agreeâ vs. Aiforiaâs âhereâs every cell identified in the analysis in the image and a ready draft report with numbers included - does it look right and do you approve the report?â), and they may well be marginalized on the platform. In this case, Aiforia just collects the points: âWe have the best platform with our models, but you can also use our competitorsâ models if you wish.â
In the long run, the situation is fundamentally different, of course, as model differences are expected to narrow, and Aiforia will inevitably be weaker in some areas even in the most bullish scenario. If Aiforia is still the labâs main platform, the company will likely collect some kind of resale fee (note: almost pure margin) for each analysis performed with a competitorâs model. This could be a good development for Aiforia (and also for the development of the industry) if investments in model development are shared among several companies.
Thereâs a fairly reasonable comparison point in the smartphone ecosystem â if Aiforia succeeds in winning a significant portion of labsâ platform deals (cf. Apple/Google), they will become one of the strongest platforms in the market from the perspective of model availability for this customer base (and with the support of their own models) (cf. iOS/Android), where competitors will want to bring their models in addition to their own (cf. AppStore/Play Store). Other platforms, besides these few leading ones, will shift to developing only models (App Developers) and will practically not gain a reasonable market share for their own platform, because other players have no incentive to bring their models to a platform from which they donât get volumes.
42 Likes
This kind of blog post from Aiforiaâs website. I myself understood about 10% of the text.
(Summary made and translated with ChatGPT.)
Dr. Maxwell L. Smith from Mayo Clinic has developed artificial intelligence models that help accurately differentiate subtypes of interstitial lung disease (ILD) based on histological features. These models can be used to analyze lung tissue scarring and fibrosis, which is crucial in diagnosing UIP and other ILD subtypes. This improves diagnostic accuracy and can lead to better treatment decisions, as ILD subtypes have different prognoses and treatment responses. AI thus offers a new tool for pathologists and supports multidisciplinary diagnostics.
13 Likes
To my recollection (feel free to correct me if Iâm wrong), Mayo and Aiforia have some kind of agreement that allows Aiforia to make resales of that kind of development.
6 Likes
Mr. Smith has been productive. Thereâs also another recent article on Aiforiaâs website:
11 Likes
Something is happening, as more sales power is being sought @usa
https://careers.aiforia.com/jobs/5315489-account-executive?_gl=1*c2zh4l*_gcl_au*MTM2MjYxODg1NC4xNzM2MjM1NDMy&utm_content=322171503&utm_medium=social&utm_source=linkedin&hss_channel=lcp-3700181
15 Likes